Journal Officiel De L'union Européenne 23.9.2003

Total Page:16

File Type:pdf, Size:1020Kb

Journal Officiel De L'union Européenne 23.9.2003 450 FR Journal officiel de l'Union européenne 23.9.2003 Appendice A visé au Chapitre 1, point 2, de l'annexe XI (*) Liste, fournie en une seule langue par Malte, des médicaments pour lesquels l'autorisation de mise sur le marché délivrée en vertu du droit maltais avant la date d'adhésion demeurera valable jusqu'à ce qu'elle soit renouvelée conformément à l'acquis ou jusqu'au 31 décembre 2006, si cette dernière date est plus proche. L'inscription d'un médicament sur cette liste ne signifie pas forcément que l'autorisation de mise sur le marché obtenue est conforme à l'acquis. LISTE DES MÉDICAMENTS À INCLURE DANS L'ARRANGEMENT NÉGOCIÉ DANS LE CADRE DU CHAPITRE I Trade Name Dosage Form Dose MA Holder Country 0.45% SODIUM CHLORIDE IN 5% INFUSION SOLUTION N/A B.BRAUN MELSUNGEN GERMANY GLUCOSE AG 0.45% SODIUM CHLORIDE SOLUTION FOR 0.45% ABBOTT LABORATORIES UNITED STATES OF INJECTION USP INJECTION AMERICA 0.45% SODIUM CHLORIDE SOLUTION FOR IV 4.5MG/ML ABBOTT LABORATORIES UNITED STATES OF INJECTION, USP INJECTION AMERICA 0.9% SOD. CHLORIDE AND 5% SOLUTION FOR N/A BAXTER HEALTHCARE UNITED KINGDOM GLUCOSE INJECTION LIMITED 0.9% SODIUM CHLORIDE AND 5% INFUSION SOLUTION N/A B.BRAUN MELSUNGEN GERMANY GLUCOSE IV INF AG 0.9% SODIUM CHLORIDE SOLUTION FOR INJ 9MG/ML ABBOTT LABORATORIES UNITED STATES OF INJECTION AMERICA 0.9% SODIUM CHLORIDE SOLUTION FOR 0.9% ABBOTT LABORATORIES UNITED STATES OF INJECTION USP INJECTION AMERICA 0.9% SODIUM CHLORIDE SOLUTION FOR 0.9% ABBOTT LABORATORIES UNITED STATES OF INJECTION USP INJECTION AMERICA 0.9% SODIUM CHLORIDE SOLUTION FOR 9MG/ML ABBOTT LABORATORIES UNITED STATES OF IRRIGATION IRRIGATION AMERICA 0.9% SODIUM CHLORIDE SOLUTION FOR 0.9% ABBOTT LABORATORIES UNITED STATES OF IRRIGATION USP IRRIGATION AMERICA 0.9% W/V SODIUM CHLORIDE SOLUTION FOR 0.9% W/V B.BRAUN MELSUNGEN GERMANY INJECTION BP INJECTION AG 0.9% W/V SODIUM CHLORIDE IRRIGATION SOLUTION 0.9% W/V B.BRAUN MELSUNGEN GERMANY IRRIGATION SOL. AG 0.9% W/V SODIUM CHLORIDE IV INFUSION SOLUTION 0.9% W/V B.BRAUN MELSUNGEN GERMANY INFUSION BP AG 1% W/V LIDOCAINE INJECTION INJECTION SOLUTION 1% W/V B.BRAUN MELSUNGEN GERMANY AG 1.5% GLYCINE IRRIGATION IRRIGATION SOLUTION 15MG/ML ABBOTT LABORATORIES UNITED STATES OF SOLUTION USP AMERICA 1.5% GLYCINE IRRIGATION USP SOLUTION FOR 15MG/ML ABBOTT LABORATORIES UNITED STATES OF IRRIGATION AMERICA 1.5% W/V GLYCINE IRRIGATION IRRIGATION SOLUTION 1.5% W/V B.BRAUN MELSUNGEN GERMANY SOL. BP AG 1/2 STRENGTH CMPD. SODIUM SOLUTION FOR N/A BAXTER HEALTHCARE UNITED KINGDOM LACTATE + GLUC INJECTION LIMITED (*) Pour le texte de l'annexe XI, voir JO L 236 du 23.9.2003, p. 859. 23.9.2003 FR Journal officiel de l'Union européenne 451 Trade Name Dosage Form Dose MA Holder Country 10% CALCIUM CHLORIDE SOLUTION FOR 100MG/ML ABBOTT LABORATORIES UNITED STATES OF INJECTION AMERICA 10% CALCIUM CHLORIDE SOLUTION FOR 100MG/ML ABBOTT LABORATORIES UNITED STATES OF INJECTION USP (ABBOJECT INJECTION AMERICA INJECTION) 10% DEXTROSE AND 0.225% SOLUTION FOR N/A ABBOTT LABORATORIES UNITED STATES OF SODIUM CHLORIDE US INJECTION AMERICA 10% DEXTROSE AND 0.225% SOLUTION FOR NA ABBOTT LABORATORIES UNITED STATES OF SODIUM CHLORIDE INJECTION INJECTION AMERICA USP 10% DEXTROSE INJECTION USP SOLUTION FOR 100MG/ML ABBOTT LABORATORIES UNITED STATES OF INJECTION AMERICA 10% DEXTROSE INJECTION USP SOLUTION FOR 10% ABBOTT LABORATORIES UNITED STATES OF INJECTION AMERICA 10% MANNITOL I.V. INJECTION SOLUTION FOR 100MG/ML ABBOTT LABORATORIES UNITED STATES OF INJECTION LTD. AMERICA 10% MANNITOL IV INJECTION SOLUTION FOR 10% ABBOTT LABORATORIES UNITED STATES OF INJECTION AMERICA 10% MANNITOL IV INJECTION USP SOLUTION FOR 10% ABBOTT LABORATORIES UNITED STATES OF INJECTION AMERICA 10% W/V CALCIUM GLUCONATE INJECTION SOLUTION 10% W/V B.BRAUN MELSUNGEN GERMANY INJECTION BP AG 10% W/V GLUCOSE INTRAVENOUS INFUSION SOLUTION 10% W/V B.BRAUN MELSUNGEN GERMANY INFUSION BP AG 10%DEXTROSE AND 0.225% SOLUTION FOR IV N/A ABBOTT LABORATORIES UNITED STATES OF SODIUM CHLORIDE INJ INJECTION AMERICA 1G VENA N I.V. 2.5G/50ML SOL FOR I.V INF 2.5G/50ML KEDRION S.P.A. ITALY 1G VENA N I.V SOL FOR IV INF 10G/200ML KEDRION S.P.A. ITALY 1G VENA N I.V. 1G/20ML SOL FOR IV INF 1G/20ML KEDRION S.P.A. ITALY 1G VENA N I.V. 5G/100ML SOL FOR IV INF 5G/100ML KEDRION S.P.A. ITALY 2% LIDOCAINE HCL INJECTION SOLUTION FOR 20MG/ML ABBOTT LABORATORIES UNITED STATES OF USP INJECTION AMERICA 2% W/V LIDOCAINE INJECTION INJECTION SOLUTION 2% W/V B.BRAUN MELSUNGEN GERMANY AG 20% DEXTROSE INJECTION USP SOLUTION FOR 20% ABBOTT LABORATORIES UNITED STATES OF INJECTION AMERICA 20% DEXTROSE INJECTION, USP SOLUTION FOR IV 200MG/ML ABBOTT LABORATORIES UNITED STATES OF INJECTION AMERICA 20% MANNITOL IV INJECTION SOLUTION FOR 200MG/ML ABBOTT LABORATORIES UNITED STATES OF INJECTION AMERICA 20% MANNITOL IV INJECTION USP SOLUTION FOR 20% ABBOTT LABORATORIES UNITED STATES OF INJECTION AMERICA 20% W/V CALCIUM GLUCONATE SOLUTION FOR 20% W/V B.BRAUN MELSUNGEN GERMANY INJECTION BP INJECTION AG 20% W/V GLUCOSE INTRAVENOUS INFUSION SOLUTION 20% W/V B.BRAUN MELSUNGEN GERMANY SOLUTION BP AG 30% W/V GLUCOSE INJECTION BP INFUSION SOLUTION 30% W/V B.BRAUN MELSUNGEN GERMANY AG 452 FR Journal officiel de l'Union européenne 23.9.2003 Trade Name Dosage Form Dose MA Holder Country 37.5%W/V GLUCOSE WITH INFUSION SOLUTION N/A B.BRAUN MELSUNGEN GERMANY ELECTROLYTES IVI AG 3-CIF POWDER FOR INJECTION 1000MG ELSAAD PHARMA SYRIA 4.2% W/V SODIUM BICARBONATE INFUSION SOLUTION N/A B.BRAUN MELSUNGEN GERMANY IVI BP AG 40% W/V GLUCOSE INJECTION BP INFUSION SOLUTION 40% W/V B.BRAUN MELSUNGEN GERMANY CONCENT AG 40% W/V GLUCOSE INTRAVENOUS INFUSION SOLUTION 40% W/V B.BRAUN MELSUNGEN GERMANY INFUSION BP AG 5% DEXTROSE AND 0.225% NACL SOLUTION FOR NA ABBOTT LABORATORIES UNITED STATES OF INJECTION INJECTION AMERICA 5% DEXTROSE AND 0.225% SOLUTION FOR N/A ABBOTT LABORATORIES UNITED STATES OF SODIUM CHLORIDE INJ INJECTION AMERICA 5% DEXTROSE AND 0.45% NACL SOLUTION FOR NA ABBOTT LABORATORIES UNITED STATES OF INJ. INJECTION AMERICA 5% DEXTROSE AND 0.45% SODIUM SOLUTION FOR IV INJ N/A ABBOTT LABORATORIES UNITED STATES OF CHLORIDE INJ AMERICA 5% DEXTROSE AND 0.9% NACL SOLUTION FOR NA ABBOTT LABORATORIES UNITED STATES OF INJ. INJECTION AMERICA 5% DEXTROSE AND 0.9% SODIUM SOLUTION FOR IV INJ N/A ABBOTT LABORATORIES UNITED STATES OF CHLORIDE INJ AMERICA 5% DEXTROSE AND LACTATED SOLUTION FOR IV N/A ABBOTT LABORATORIES UNITED STATES OF RINGER'S INJ USP INFUSION AMERICA 5% DEXTROSE INJECTION USP SOLUTION FOR 5% ABBOTT LABORATORIES UNITED STATES OF INJECTION AMERICA 5% DEXTROSE INJECTION, USP SOLUTION FOR 50MG/ML ABBOTT LABORATORIES UNITED STATES OF INJECTION AMERICA 5% W/V GLUCOSE INJECTION BP SOLUTION FOR 5% W/V B.BRAUN MELSUNGEN GERMANY INJECTION AG 5% W/V GLUCOSE INTRAVENOUS INFUSION SOLUTION 5% W/V B.BRAUN MELSUNGEN GERMANY INFUSION BP AG 5.85% W/V SODIUM CHLORIDE SOLUTION FOR 5.85% W/V B.BRAUN MELSUNGEN GERMANY INJECTION BP INJECTION AG 50% DEXTROSE INJECTION USP SOLUTION FOR 50% W/V ABBOTT LABORATORIES UNITED STATES OF INJECTION AMERICA 50% DEXTROSE INJECTION USP SOLUTION FOR 50% ABBOTT LABORATORIES UNITED STATES OF INJECTION AMERICA 50% DEXTROSE INJECTION, USP SOLUTION FOR 500MG/ML ABBOTT LABORATORIES UNITED STATES OF INJECTION AMERICA 50% MAGNESIUM SULFATE SOLUTION FOR IV/IM INJ 500MG/ML ABBOTT LABORATORIES UNITED STATES OF INJECTION AMERICA 50% MAGNESIUM SULFATE SOLUTION FOR 4 MEQ MG++/ML ABBOTT LABORATORIES UNITED STATES OF INJECTION, USP INJECTION AMERICA 50% MAGNESIUM SULPHATE INJ SOLUTION FOR 50% ABBOTT LABORATORIES UNITED STATES OF USP INJECTION AMERICA 50% W/V GLUCOSE INJECTION BP INFUSION SOLUTION 50% W/V B.BRAUN MELSUNGEN AG GERMANY 50% W/V GLUCOSE INJECTION BP INFUSION SOLUTION 50% W/V B.BRAUN MELSUNGEN AG GERMANY CONCENT 23.9.2003 FR Journal officiel de l'Union européenne 453 Trade Name Dosage Form Dose MA Holder Country 7.45% W/V POTASSIUM CHLORIDE SOLUTION FOR 7.45% W/V B.BRAUN MELSUNGEN GERMANY INJECTION INJECTION AG 70% W/V GLUCOSE INJECTION BP INFUSION SOLUTION 70% W/V B.BRAUN MELSUNGEN GERMANY AG 8.4% SODIUM BICARBONATE INJ SOLUTION F/INJECTION 84MG/ML ABBOTT LABORATORIES UNITED STATES OF USP AMERICA 8.4% SODIUM BICARBONATE INJ SOLUTION FOR 8.4% ABBOTT LABORATORIES UNITED STATES OF USP INJECTION AMERICA 8.4% SODIUM BICARBONATE SOLUTION FOR IV 84MG/ML ABBOTT LABORATORIES UNITED STATES OF INJECTION,USP INJECTION AMERICA 8.4% W/V SODIUM BICARBONATE INFUSION SOL. CONCEN- 8.4% W/V B.BRAUN MELSUNGEN GERMANY INJECTION BP TRATE AG 8.4%W/V SODIUM BICARBONATE INFUSION SOLUTION 8.4% W/V B.BRAUN MELSUNGEN GERMANY IV INFUSION AG AAA MOUTH AND THROAT SPRAY OROMUCOSAL SPRAY 1.5MG/SP MANX PHARMA LIMITED UNITED KINGDOM AB-ACICLOVIR 250 POWDER FOR INJECTION 250MG/VIAL ASTRAPIN PHARMA GERMANY GMBH & CO. KG AB-DICLOFENAC 75 SOLUTION FOR 75MG/3ML ASTRAPIN PHARMA GERMANY INJECTION GMBH & CO.KG ABDINE COLD RELIEF POWDER POWDER FOR ORAL 650MG BELL SONS & CO UNITED KINGDOM SOLUTION (DRUGGISTS) LIMITED AB-ERYTHROMYCIN 1000 POWDER FOR INJECTION 1000MG ASTRAPIN PHARMA GERMANY GMBH & CO.KG AB-HYDROCORTISONE 100 POWDER FOR INJECTION 100MG ASTRAPIN PHARMA GERMANY GMBH & CO. KG ABIDEC DROPS ORAL SOLUTION N/A WARNER-LAMBERT UNITED KINGDOM CONSUMER HEALTHCARE ABIDEC DROPS ORAL SOLUTION N/A PFIZER CONSUMER UNITED KINGDOM HEALTHCARE AB-METHYLPREDNISOLONE SUSPENSION FOR 40MG/ML ASTRAPIN PHARMA GERMANY ACETATE 40 INJECTION GMBH & CO. KG AB-METOCLOPRAMIDE HCL 10 SOLUTION FOR 10MG/2ML ASTRAPIN PHARMA GERMANY INJECTION GMBH & CO.
Recommended publications
  • NEW Products
    NEW Products NEW Products - January 2021 NEW Generics PIP CODE PRODUCT PACK 1236082 Dexamethasone Tablets 500mcg 28 7747462 Diltiazem Tablets 60mg 84 5018957 Mebeverine 50mg/5ml Oral Suspension 300ml NEW UK Feeds PIP CODE PRODUCT PACK 3655545 Fresubin 2kcal Fibre Apricot/Peach 4x200m 3 NEW Products 3442803 Fresubin 2kcal Fibre Cappucino 4x200m 3438264 Fresubin 2kcal Fibre Chocolate 4x200m 3442795 Fresubin 2kcal Fibre Lemon 4x200m 5 Generics 3655537 Fresubin 2kcal Fibre Neutral 4x200m www.de-group.co.uk 3442944 Fresubin 2kcal Fibre Vanilla Pack 4x200m 4022950 Fresubin 2kcal Mini Apricot/Peach 4x125m 44 Parallel Imports 4022976 Fresubin 2kcal Mini Fibre Chocolate 4x125m 4022984 Fresubin 2kcal Mini Fibre Vanilla 4x125m 4022968 Fresubin 2kcal Mini FOTF 4x125m 3 60 UK Ethicals 4022943 Fresubin 2kcal Mini Vanilla 4x125m 3771334 Polycal Liquid Bottle Neutral 200ml 3771326 Polycal Liquid Bottle Orange 200ml 70 UK Feeds NEW UK Dressings PIP CODE PRODUCT PACK 74 Parallel Import Feeds 3272887 Airzone Peak Flow Meter 15 3793965 Biatain Adhesive 7.5x7.5 10 3798469 Clinifilm Wipes 30 76 Dressings 3902756 Clinimed LBF Foam Applicator 2ml 5 2896439 Clinimed LBF NonSting Bar Film Wipes 30 90 3694924 Cutimed Protect Cream 90g OTC 3694916 Cutimed Protect Cream 28g 3694890 Cutimed Protect Foam 1ml 5 3694908 Cutimed Protect Foam 3ml 5 134 Dispensing 3694882 Cutimed Protect Spray 28ml 3722238 Cutimed Sorbion Sachet Extra 20x10 5 3883402 Cutimed Sorbion Sachet XL 45cmx25cm 5 136 Vets 3942018 Devon Foot And Heel Protector 2 227074 Kaltostat Rope Cavity Wound
    [Show full text]
  • Pharmaceutical Sector
    MARKET REVIEW ON PRIORITY SECTOR UNDER COMPETITION ACT 2010 PHARMACEUTICAL SECTOR Malaysia Competition Commission (MyCC) 27 December 2017 TABLE OF CONTENTS Executive Summary 2 List of Abbreviations 7 Glossary 9 Introduction 16 Methodology and Limitations 18 Policy Context for the Review 24 PART ONE: OVERVIEW OF MALAYSIA’s PhARMACEUTICAL SECtor Chapter 1: Overall Growth of the Healthcare and Pharmaceutical Sectors 28 Chapter 2: Market Structure and Supply Chain 41 Chapter 3: Market Share and Market Concentration 69 Chapter 4: Market Dominance and Impact on Availability, Affordability and Accessibility of Medicines 93 PART TWO: COMPETITION CONCERNS IN THE PHARMACEUTICAL SECtor Chapter 5: Key Existing Laws and Regulations and An Assessment of Impacts 118 Chapter 6: Competition Concerns Among Industry Players 148 Chapter 7: Selected Case Studies on Anti-Competitive Conduct 177 PART THREE: CONCLUSION AND RECOMMENDatIONS Chapter 8: Conclusion and Recommendations 208 APPENDICES Appendix 1: Guiding Questions for Interviews with Industry Players 224 Appendix 2: Malaysian Organization of Pharmaceutical Industries (MOPI) Members 229 Appendix 3: Brief Profiles of Top 6 Malaysian Local/Joint Venture Pharmaceutical Companies 230 Appendix 4: Pharmaceutical Association of Malaysia (PhAMA) Members 232 Appendix 5: Malaysian Association of Pharmaceutical Suppliers (MAPS) Members 233 Appendix 6: Drug Registration Process 234 References 236 EXECUTIVE SUMMARY The aims of Malaysia’s National Medicines Policy are to promote equitable access to, and rational use of, safe, effective and affordable medicines by its population. In order to maximize social welfare, this policy is strengthened by Malaysia’s Competition Act of 2010 and the establishment of the Malaysia Competition Commission (MyCC) to bring about allocation, production and innovation efficiencies.
    [Show full text]
  • Laws of Trinidad and Tobago Ministry of Legal Affairs
    LAWS OF TRINIDAD AND TOBAGO MINISTRY OF LEGAL AFFAIRS www.legalaffairs.gov.tt FOOD AND DRUGS ACT CHAPTER 30:01 Act 8 of 1960 Amended by 39 of 1968 156/1972 *31 of 1980 16 of 1986 12 of 1987 6 of 1993 16 of 1998 6 of 2005 *See Note on Validation at page 2 Current Authorised Pages Pages Authorised (inclusive) by L.R.O. 1–2 .. 3–20 .. 21–245 .. UNOFFICIAL VERSION L.R.O. UPDATED TO DECEMBER 31ST 2014 LAWS OF TRINIDAD AND TOBAGO MINISTRY OF LEGAL AFFAIRS www.legalaffairs.gov.tt 2 Chap. 30:01 Food and Drugs Index of Subsidiary Legislation Page Food and Drugs Regulations (GN 130/1964) … … … … 25 Official Method Notification (GN 54/1972) … … … … 124 *Approval of New Drugs Notification … … … … … 129 †Withdrawal of Approval of New Drugs Notification (GN 51/1969) … … 200 Fish and Fishery Products Regulations (LN 220/1998)…………201 †This Notification (i.e. 51/1969) has been amended by LNs 99 and 114/1984 which have been omitted. *Note on Approval of New Drugs Notification The list of new drugs set out in the Schedule to this Notification has been consolidated as at 31st December 1977. This list is so voluminous and changes to it so frequent that, especially in view of its very limited use by the general public, it is not practicable to update it annually. The references to the amendments to this list since 31st December 1977 are contained in the Current Consolidated Index of Acts and Subsidiary Legislation. †Note on Withdrawal of Approval of New Drugs Notification For references to the Withdrawal of Approval of New Drugs Notifications subsequent to the year 1969 — See the current Consolidated Index of Acts and Subsidiary Legislation.
    [Show full text]
  • Cambridgeshire Joint Prescribing Group 2004
    Date Printed 13/12/201722/11/201721/11/201728/09/2017 Current Commissioning Indication Last date Relevant Approved name Classification and Responsibility Rationale for Next Review Covered by this classified by NICE (Brand Name) Priority Funding Decision Due Classification CPJPG Guidance Position NHSE CCG CAMBRIDGESHIRE & PETERBOROUGH CCG FORMULARY Classification of Prescribing Responsibility Skip to Alphabetical Index Foreword This document is an appendix to the Cambridgeshire and Peterborough CCG Formulary Medicines considered by the CPJPG are included in this document. In general, only medicines classified as ‘NOT RECOMMENDED’ and ‘HOSPITAL ONLY’ are retained in this document long-term whilst all others are removed after 6 months as they are included in the CCG Formulary. Definitions of the recommendations made by the Cambridgeshire and Peterborough Joint Prescribing Group (CPJPG) can be found in the explanatory notes Any medication/drug licensed or becoming available after the revision date (below) for this document and not considered by CPJPG should be regarded as ‘Not Recommended’ or ‘Hospital only’. Omission of a drug from this table cannot be taken to indicate that it is recommended for prescribing in either primary or secondary care. (i.e. any medicine not listed in either the classification table or the formulary are classified as “Not recommended” ) Please contact the Medicines Management Team for further advice. Cambridgeshire and Peterborough CCG have undertaken a prioritisation process and agreed that some therapies will not be a priority for funding and will therefore not be funded other than in exceptional circumstances. This appendix to the formulary is a continually evolving document and will be updated after each CPJPG meeting (every 2 months).
    [Show full text]
  • Food and Drugs Act 2005
    LAWS OF TRINIDAD AND TOBAGO MINISTRY OF LEGAL AFFAIRS www.legalaffairs.gov.tt FOOD AND DRUGS ACT CHAPTER 30:01 Act 8 of 1960 Amended by 39 of 1968 156/1972 *31 of 1980 16 of 1986 12 of 1987 6 of 1993 16 of 1998 6 of 2005 *See Note on Validation at page 2 Current Authorised Pages Pages Authorised (inclusive) by L.R.O. 1–2 .. 1/2009 3–20 .. 1/2006 21–245 .. 1/2009 L.R.O. 1/2009 UPDATED TO DECEMBER 31ST 2009 LAWS OF TRINIDAD AND TOBAGO MINISTRY OF LEGAL AFFAIRS www.legalaffairs.gov.tt 2 Chap. 30:01 Food and Drugs Index of Subsidiary Legislation Page Food and Drugs Regulations (GN 130/1964) … … … … 25 Official Method Notification (GN 54/1972) … … … … 124 *Approval of New Drugs Notification … … … … … 129 †Withdrawal of Approval of New Drugs Notification (GN 51/1969) … … 200 Fish and Fishery Products Regulations (LN 220/1998)…………201 †This Notification (i.e. 51/1969) has been amended by LNs 99 and 114/1984 which have been omitted. *Note on Approval of New Drugs Notification The list of new drugs set out in the Schedule to this Notification has been consolidated as at 31st December 1977. This list is so voluminous and changes to it so frequent that, especially in view of its very limited use by the general public, it is not practicable to update it annually. The references to the amendments to this list since 31st December 1977 are contained in the Current Consolidated Index of Acts and Subsidiary Legislation. †Note on Withdrawal of Approval of New Drugs Notification For references to the Withdrawal of Approval of New Drugs Notifications subsequent to the year 1969 — See the current Consolidated Index of Acts and Subsidiary Legislation.
    [Show full text]
  • Bk Sans 005737.Pdf
    TABLE OF CONTENTS Procter & Gamble’s Earnings Per Share .3 Coca-Cola’s Earnings Per Share .3 Johnson & Johnson’s Earnings Per Share .4 United Continental’s Earnings Per Share .4 Ford Motor Company’s Earnings Per Share .5 Advance Micro Devices, Inc.’s Earnings Per Share .5 Compare Coca-Cola to Ford Motor Company .6 American Express Company .7 American Express Company Per Share Earnings History .8 The Bank of New York Mellon (BNY Mellon) .9 BNY Mellon EPS History / BNY Mellon BVPS History .10 Coca-Cola Company .11 ConocoPhillips .12 ConocoPhillips EPS History / ConocoPhillips BVPS History .13 Costco Wholesale Corporation .14 Costco EPS History / Costco BVPS History .15 GlaxoSmithKline .16 GSK’s brand-name products .17 GlaxoSmithKline’ Profile / GlaxoSmithKline’ History .18 Johnson & Johnson .19 Johnson & Johnson Per Share Book Value History .20 Kraft Foods, Inc .21 Kraft Foods EPS History / Kraft Foods BVPS History .22 Moody’s Corporation .23 Moody’s Corporation EPS History .24 Procter & Gamble Company .25 Procter & Gamble BVPS History .26 Sanofi S. A. .27 Sanofi A.S EPS ADR History / Sanofi A.S BVPS History .28 Torchmark Corporatio .29 Torchmark Corporation EPS History / Torchmark Corporation BVPS History .30 Union Pacific Corporation .31 Union Pacific Corporation NPM (Net Profit Margin) History .32 Union Pacific Corporation BVPS History / Union Pacific Corporation EPS History .32 U.S. Bancorp .33 U.S. Bankcorp EPS History / U.S. Bankcorp BVPS History .34 Wal-Mart Stores, Inc. .35 Walmart EPS History / Walmart BVPS History .36 Washington
    [Show full text]
  • Additions to the Automation List from 1St January 2012
    Additions to the Automation List from 1st January 2012 Acular Drops .5 % Packsize 5 Broflex Syrup 5 Mg/5ml Packsize 200 Alfacalcidol Drops 2 Mcg/Ml Packsize 10 Brolene Drops .1 % Packsize 10 Alimemazine Tartrate Syrup 30 Mg/5ml Packsize 100 Budelin Novolizer Inhal 200 Mcg/Dose Packsize 1 Alomide Drops .1 % Packsize 5 Budelin Novolizer Inhal 200 Mcg/Dose Packsize 1 Alpha Tocopheryl Acetate Susp 500 Mg/5ml Budesonide Inhal 200 Mcg/Dose Packsize 1 Packsize 100 Budesonide Inhal 200 Mcg/Dose Packsize 1 Altacite Plus Susp Packsize 100 Budesonide Inhal 400 Mcg/Dose Packsize 1 Altacite Plus Susp Packsize 500 Budesonide Spray 64 Mcg/Dose Packsize 1 Alvesco Inhal 160 Mcg/Dose Packsize 1 Bumetanide Liq 1 Mg/5ml Packsize 150 Alvesco Inhal 160 Mcg/Dose Packsize 1 Buserelin Spray 150 Micrograms Packsize 2 Alvesco Inhal 80 Mcg/Dose Packsize 1 Calcitonin (Salmon) Spray 200 Units/Dose Packsize Amantadine Hydrochloride Syrup 50 Mg/5ml 1 Packsize 150 Calpol Infant Susp 120 Mg/5ml Packsize 100 Amoxicillin Syrup 125 Mg/5ml Packsize 100 Calpol Six Plus Susp 250 Mg/5ml Packsize 100 Amoxicillin Syrup 250 Mg/5ml Packsize 100 Calpol Six Plus Susp 250 Mg/5ml Packsize 200 Ampicillin Susp 125 Mg/5ml Packsize 100 Calprofen Susp 100 Mg/5ml Packsize 100 Anbesol Liq Packsize 15 Canesten Af Spray 1 % Packsize 1 Anbesol Liq Packsize 6.5 Canesten Spray 1 % Packsize 1 Antepsin Susp 1 G/5ml Packsize 250 Carbocisteine Syrup 125 Mg/5ml Packsize 300 Apraclonidine Drops .5 % Packsize 5 Carmellose Sodium Drops .5 % Packsize 30 Apraclonidine Drops 1 % Packsize 24 Carmellose Sodium
    [Show full text]
  • Overview: Malaysian Healthcare Biotechnology
    Overview: Malaysian Healthcare Biotechnology The Malaysian Healthcare Biotechnology Sector A Frost & Sullivan Whitepaper 2009 1 Contents Please note; all data included in this paper is from published sources or Frost & 04 •Introduction Sullivan’s proprietary information, or from industry participants. Where currencies are mentioned, the conversion of Malaysian Ringgit to US Dollar 05 •Goals and Strategies for the Sector uses the following exchange rate: RM 3.6 = US$1.0 Malaysian Biotechnology Policy Disclaimer 9th Malaysia Plan Information, opinions or recommendations provided by Frost & Sullivan are presented solely for informational purposes. The information used and statements of fact made 08 •Malaysian Healthcare: Over the years and today have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy of such statements. The information presented 10 •Healthcare Biotechnology Focus Areas and the opinions expressed are subject to change without notice. Frost & Sullivan Focus Sector Overview: CMO takes no responsibility for any incorrect information supplied to us by published Focus Sector Overview: CRO sources or industry participants; however all care is taken to verify data. Quantitative Focus Sector Overview: Biopharmaceuticals/Biogenerics market information is subject to fluctuation. In no event will Frost & Sullivan or Focus Sector Overview: Medical Devices & Diagnostics employees thereof be liable for any decision made or action taken in reliance on the Focus Sector Overview: Therapeutics information in this report or for any consequential, special or similar damages, even if Focus Sector Overview: Drug discovery and Drug Delivery advised of the possibility of such damages. About Frost & Sullivan 17 •Key Success Factors Frost & Sullivan, a global growth consulting company, has been partnering with Biodiversity: Healthcare/Therapeutics clients to support the development of innovative strategies for more than 45 years.
    [Show full text]
  • Dokumenti” ES 13
    “Latvijas Vēstnesis. Dokumenti” ES 13. burtnīca Eiropas Savienības dokumenti LATVIJAS REPUBLIKASLALA OFICIÅLAISTVIJAS TVIJASLAIKRAKSTS V‰STNESISV‰STNESIS VALSTS NORMATÈVIE TIESÈBU AKTI Galvenais redaktorsLA — OSKARS GERTVIJASTS V‰STNESIS DOKUMENTI 2004.gads, 10.februåris EIROPAS SAVIENÈBAS DOKUMENTI EIROPAS SAVIENĪBAS DOKUMENTI Oficiålå publikåcija ES 13. burtnîca TRATADO RELATIVO A LA ADHESIÓN A LA UNIÓN EUROPEA 2003 SMLOUVA O PŘISTOUPENÍ K EVROPSKÉ UNII 2003 TRAKTAT OM TILTRÆDELSE AF DEN EUROPÆISKE UNION 2003 VERTRAG ÜBER DEN BEITRITT ZUR EUROPÄISCHEN UNION 2003 2003. AASTA EUROOPA LIIDUGA ÜHINEMISE LEPING ΣΥΝΘΗΚΗ ΠΡΟΣΧΩΡΗΣΕΩΣ ΣΤΗΝ ΕΥΡΩΠΑΪΚΗ ΕΝΩΣΗ 2003 TREATY OF ACCESSION TO THE EUROPEAN UNION 2003 TRAITE RELATIF A L’ADHESION A L’UNION EUROPEENNE DE 2003 CONRADH AONTACHAIS LEIS AN AONTAS EORPACH 2003 TRATTATO DI ADESIONE ALL’UNIONE EUROPEA 2003 LĪGUMS PAR PIEVIENOŠANOS EIROPAS SAVIENĪBAI, 2003 2003 M. STOJIMO Į EUROPOS SĄJUNGĄ SUTARTIS AZ EURÓPAI UNIÓHOZ TÖRTÉNŐ CSATLAKOZÁSRÓL SZÓLÓ SZERZŐDÉS 2003 IT-TRATTAT TA’ L-ADEŻJONI MA’ L-UNJONI EWROPEA 2003 VERDRAG BETREFFENDE DE TOETREDING TOT DE EUROPESE UNIE 2003 TRAKTAT O PRZYSTĄPIENIU DO UNII EUROPEJSKIEJ 2003 TRATADO DE ADESÃO À UNIÃO EUROPEIA DE 2003 ZMLUVA O PRISTÚPENÍ K EURÓPSKEJ ÚNII 2003 POGODBA O PRISTOPU K EVROPSKI UNIJI 2003 SOPIMUS LIITTYMISESTÄ EUROOPAN UNIONIIN 2003 FÖRDRAGET OM ANSLUTNING TILL EUROPEISKA UNIONEN 2003 Akts par pievienošanās nosacījumiem un pielāgojumiem līgumos, kas ir Eiropas Savienības pamatā X I p i e l i k u m s. Pievienošanās akta 24. pantā minētais saraksts: Malta P i e l i k u m a Farmaceitisko produktu saraksts, kas iekļaujams pie pasākumiem, A p a p i l d i n ā j u m s.
    [Show full text]
  • Medicine Procurement Prices and Processesin the United Nations Relief
    medicine procurement prices and processes in the united nations relief and works agency for palestine refugees in the near east (UNRWA) december 2011 "© United Nations Relief and Works Agency for Palestine Refugees in the Near East, 2012. All rights reserved. The views expressed in this report are those of the author(s) and do not necessarily reflect the views of UNRWA. UNRWA does not endorse or recommend specific medicines, companies or products of manufacturers, whether or not mentioned in this report. UNRWA does not warrant that the information contained in this publication is complete and correct and shall not be liable for any damages incurred as a result of its use." 2 Table of Contents Abbreviations .............................................................................................................................. 5 Foreword .................................................................................................................................... 6 Executive Summary ..................................................................................................................... 7 1. Introduction ......................................................................................................................... 8 2. Objectives .......................................................................................................................... 10 3. Methodology ..................................................................................................................... 11 3.1 Data collection
    [Show full text]
  • Introduction to Renal Therapeutics
    Introduction to Renal Therapeutics Introduction to Renal Therapeutics Edited by Caroline Ashley MSc, BPharm (Hons), MRPharmS Lead Specialist Pharmacist, Renal Services Royal Free Hospital Royal Free Hampstead NHS Trust London, UK Clare Morlidge BPharm (Hons), DipClinPharm, MRPharmS Cardiothoracic Directorate Pharmacist Lister Hospital East and North Hertfordshire NHS Trust Hertfordshire, UK On behalf of the UK Renal Pharmacy Group London • Chicago Published by the Pharmaceutical Press An imprint of RPS Publishing 1 Lambeth High Street, London SE1 7JN, UK 100 South Atkinson Road, Suite 200, Grayslake, IL 60030–7820, USA © Pharmaceutical Press 2008 is a trade mark of RPS Publishing RPS Publishing is the publishing organisation of the Royal Pharmaceutical Society of Great Britain First published 2008 Typeset by Photoprint, Torquay, Devon Printed in Great Britain by Cambridge University Press, Cambridge ISBN 978 0 85369 688 9 All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, without the prior written permission of the copyright holder. The publisher makes no representation, express or implied, with regard to the accuracy of the information contained in this book and cannot accept any legal responsibility or liability for any errors or omissions that may be made. The right of Caroline Ashley and Clare Morlidge to be identified as the authors of this work has been asserted by them in accordance with the Copyright, Designs and Patents Act, 1988. A catalogue
    [Show full text]
  • Full Automation List
    Automation List from 1st March 2012 Abidec Drops Packsize 25 Adalimumab Inj 40 Mg/0.8ml Solution For Injection In Prefilled Abilify Tabs 10 Mg Packsize 28 Pen Packsize 2 Abstral Tabs 100 Micrograms Packsize 10 Adalimumab Inj 40 Mg/0.8ml Solution For Injection In Prefilled Abstral Tabs 100 Micrograms Packsize 30 Syringe Packsize 2 Abstral Tabs 200 Micrograms Packsize 10 Adapalene Cream .1 % Packsize 45 Abstral Tabs 200 Micrograms Packsize 30 Adapalene Gel .1 % Packsize 45 Abstral Tabs 300 Micrograms Packsize 10 Adartrel Tabs 2 Mg Packsize 28 Abstral Tabs 300 Micrograms Packsize 30 Adartrel Tabs 250 Micrograms Packsize 12 Abstral Tabs 400 Micrograms Packsize 10 Adartrel Tabs 500 Micrograms Packsize 28 Abstral Tabs 400 Micrograms Packsize 30 Adcal 1.5 G Sf Contains Calcium 600mg Chewable Tabs Abstral Tabs 600 Micrograms Packsize 30 Packsize 100 Acamprosate Calcium 333 Mg Ec Tabs Packsize 168 Adcal D3 Chewable Tabs Packsize 112 Acarbose Tabs 100 Mg Packsize 90 Adcal D3 Chewable Tabs Packsize 112 Acarbose Tabs 50 Mg Packsize 90 Adcal D3 Chewable Tabs Packsize 56 Accolate Tabs 20 Mg Packsize 56 Adcal D3 Chewable Tabs Packsize 56 Accupro Tabs 10 Mg Packsize 28 Adcal D3 Dissolve Effervescent Tabs Packsize 56 Accupro Tabs 20 Mg Packsize 28 Adcal D3 Tabs Packsize 112 Accupro Tabs 40 Mg Packsize 28 Adefovir Dipivoxil Tabs 10 Mg Packsize 30 Accupro Tabs 5 Mg Packsize 28 Adenuric Tabs 80 Mg Packsize 28 Accuretic Tabs Packsize 28 Adipine 10 Mr 10 Mg Tabs Packsize 56 Acebutolol Caps 100 Mg Packsize 84 Adipine 20 Mr 20 Mg Tabs Packsize 56 Acebutolol
    [Show full text]